By Suherman Candra Maholtra 
In a significant stride toward addressing one of the most resilient public health challenges in human history, researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have announced the development of an experimental DNA-based therapeutic vaccine for tuberculosis (TB). Unlike traditional preventative vaccines, this candidate is designed to be administered through the nose and functions as a therapeutic adjunct to existing antibiotic regimens. Its primary target is a specific subpopulation of the Mycobacterium tuberculosis bacteria known as "persisters"—microbes that enter a state of dormancy or drug tolerance, allowing them to survive months of intensive antibiotic therapy and eventually trigger a relapse in patients who appeared to be cured.
The study, recently published in the Journal of Clinical Investigation, details a multi-year effort to refine an immunotherapy that leverages the body’s own immune system to finish the job that antibiotics often leave incomplete. By focusing on the biological mechanisms that allow TB to hide within human tissue, the Johns Hopkins team has provided a potential blueprint for shortening TB treatment durations and combating the rising tide of multidrug-resistant tuberculosis (MDR-TB).
The Global Burden and the "Persister" Problem
Tuberculosis remains a staggering global health crisis. Despite being a curable and preventable disease, it has afflicted humanity for over 6,000 years and continues to claim more lives annually than any other single infectious pathogen, including HIV/AIDS. According to 2024 data from the World Health Organization (WHO), more than 10 million people developed active TB in the last year alone, resulting in 1.2 million deaths. Furthermore, an estimated 2 billion people—roughly one-quarter of the global population—carry a latent TB infection. While these individuals do not show symptoms and are not contagious, the bacteria remain dormant in their systems, posing a lifelong risk of reactivation.
The standard treatment for TB is notoriously grueling, typically requiring a cocktail of four antibiotics taken over six to nine months. The primary reason for this lengthy duration is the presence of "persister" bacteria. While most TB bacteria are killed quickly by drugs, persisters shift their metabolism into a slow-growing or non-growing state. In this "sleep mode," they become largely invisible to antibiotics that target active bacterial growth. If a patient stops treatment early, these persisters can re-awaken, leading to a relapse that is often more difficult to treat and more likely to be resistant to first-line drugs.
A Novel Mechanism: The Dual-Gene DNA Vaccine
The experimental vaccine developed at Johns Hopkins utilizes a sophisticated genetic approach to strip away the "stealth" capabilities of these persistent bacteria. The vaccine combines two specific genes: relMtb and Mip3α.
The relMtb gene is derived from the TB bacterium itself. It is responsible for producing a protein called RelMtb, which acts as a master switch for the bacteria’s survival under stress. When the bacteria encounter hostile environments—such as the low-oxygen conditions of a lung lesion or the chemical onslaught of antibiotics—RelMtb triggers the transition into a drug-tolerant persistent state. By including this gene in the vaccine, the researchers are essentially "training" the immune system to recognize the very protein the bacteria use to hide.
The second component, Mip3α, serves as a biological beacon. When the vaccine is administered, this gene produces a signal that attracts immature dendritic cells to the site. Dendritic cells are the "sentinels" of the immune system; their job is to capture foreign proteins (antigens) and present them to T cells, which are the specialized "soldiers" that coordinate a targeted attack. By fusing relMtb with Mip3α, the vaccine ensures that the immune system’s scouts are pulled directly to the target, facilitating a rapid and robust defense.
The Advantages of Intranasal Delivery
A key innovation of this research is the method of delivery. While most vaccines are administered via intramuscular injection, this DNA vaccine is delivered intranasally. This strategy is rooted in the basic anatomy of TB infection. Because Mycobacterium tuberculosis is an airborne pathogen that primarily infects the lungs, the researchers sought to generate "mucosal immunity"—a localized immune response within the respiratory tract.
"Intranasal delivery focuses vaccination on the respiratory mucosa in the lungs where TB infection occurs," explained Styliani Karanika, M.D., the study’s lead author and assistant professor of medicine at the Johns Hopkins University School of Medicine. This approach helps generate long-lasting, localized T-cell immunity in the airways, creating a front-line defense at the point of entry while also stimulating a systemic immune response throughout the body.
Chronology of Research and Experimental Success
The development of the Mip3α/relMtb vaccine followed a rigorous multi-stage experimental timeline, moving from molecular design to small animal models and eventually to nonhuman primates.
Phase 1: Mouse Models and Synergy with Antibiotics
In the initial stages of the study, researchers tested the vaccine in mice infected with TB. The mice were divided into groups receiving standard antibiotic therapy alone and groups receiving antibiotics combined with the intranasal vaccine. The results were stark. The vaccine-treated mice cleared the bacteria significantly faster than those receiving only drugs. Furthermore, the vaccine-treated group showed a marked reduction in lung inflammation and, perhaps most importantly, a near-total prevention of relapse after the treatment was stopped.
The researchers also tested the vaccine alongside a powerful new drug combination known as BPaL (bedaquiline, pretomanid, and linezolid), which is used for highly drug-resistant TB. The vaccine enhanced the efficacy of BPaL, suggesting that immunotherapy could be a vital tool in treating the most difficult cases where traditional drugs are failing.
Phase 2: Cellular Analysis
Detailed analysis of the lung tissue in vaccinated mice revealed a significant increase in the recruitment and activation of dendritic cells. The researchers observed a more organized structure of immune cells within the lungs, with CD4 (helper T cells) and CD8 (killer T cells) showing durable, antigen-stimulated responses. These T cells remained active and vigilant for months, providing a persistent shield against bacterial reactivation.
Phase 3: Primate Trials and Translational Bridging
To determine if the results could be replicated in a system more similar to human biology, the team evaluated the vaccine in rhesus macaques. The intranasal vaccine successfully generated measurable TB-specific immune responses in both the bloodstream and the airways of the primates. These responses were consistent with those observed in the mice that had successfully cleared the infection. The immune activity lasted for at least six months, indicating that the vaccine provides a durable window of protection.
Broader Implications for Global Health Policy
The success of this experimental vaccine aligns with the World Health Organization’s "End TB Strategy," which calls for the development of new tools, including therapeutic vaccines, to shorten treatment and reduce the global burden of the disease.
The implications of a successful therapeutic TB vaccine are profound:
- Reduced Treatment Times: If the vaccine can help antibiotics clear bacteria faster, the current six-month treatment regimen could potentially be halved, significantly increasing patient compliance.
- Combating Drug Resistance: By using the immune system to kill bacteria through a different pathway than antibiotics, the vaccine makes it much harder for the bacteria to develop resistance.
- Stability and Logistics: DNA vaccines are generally more stable than mRNA or live-attenuated vaccines. They do not require the ultra-cold storage chains that proved challenging during the COVID-19 pandemic, making them better suited for distribution in the low-resource settings where TB is most prevalent.
Future Outlook and Challenges
While the results are highly encouraging, Dr. Karanika and her colleagues emphasize that more work is needed. The primate study focused on immune activation rather than protection against an active challenge with TB bacteria. The next steps will involve efficacy studies in primates and, eventually, Phase I human clinical trials to ensure safety and dosage.
"These nonhuman primate data are encouraging because they show that the Mip3α/relMtb vaccine can generate durable, antigen-stimulated immune responses in an animal model whose immune system more closely resembles that of humans," Karanika noted. "That gives us an important translational bridge."
The research was supported by numerous grants from the National Institutes of Health (NIH) and other philanthropic organizations, reflecting the high priority placed on finding a solution to the TB epidemic. As the scientific community moves toward a post-antibiotic era where many bacterial infections are becoming untreatable, the shift toward immunotherapy—using the body’s own defenses to hunt down "persisters"—represents a vital evolution in infectious disease medicine.
If this DNA vaccine continues to prove successful in upcoming trials, it could transform the standard of care for millions, turning a 6,000-year-old plague into a manageable, and perhaps eventually eradicated, chapter of medical history.
